Results 311 to 320 of about 179,002 (365)

Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. [PDF]

Clin Hematol Int
Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, Oluwole O, Jayani R, Biltibo E, Kim TK, Sengsayadeth S, Chinratanalab W, Kitko C, Savani B, Dholaria B.   +14 more
europepmc   +1 more source

Heterogeneity of Intratumoral Microbiota Within the Tumor Microenvironment and Relationship to Tumor Development

Med Research, EarlyView.
Mutual shaping of tumor microbiota and TME. Intratumoral microbiota—comprising diverse bacteria, fungi, viruses, and intracellular organisms—play critical and dynamic roles in shaping the tumor microenvironment (TME). Their spatial and compositional diversity contributes to both intratumoral and intertumoral heterogeneity, influencing immune modulation
Zhifei Gao, Aimin Jiang, Zizhuo Li, Lingxuan Zhu, Weiming Mou, Weitao Shen, Peng Luo, Bufu Tang, Jian Zhang, Anqi Lin   +9 more
wiley   +1 more source

Sirolimus as add-on therapy to corticosteroids for moderate-severe chronic graft versus host disease. [PDF]

Blood Cell Ther
Sharma R, Pardeep A, De R, Kaundal S, Patil AN, Singh C, Jandial A, Jain A, Prakash G, Khadwal A, Malhotra P, Lad DP.   +11 more
europepmc   +1 more source

Dihydromyricetin Promotes Glucagon‐Like Peptide‐1 Secretion and Improves Insulin Resistance by Modulation of the Gut Microbiota‐CDCA Pathway

Molecular Nutrition &Food Research, Volume 69, Issue 8, April 2025.
Dihydromyricetin (DHM) administration improved insulin resistance in HFD‐induced mice through the increased serum GLP‐1 level. This benefits was mediated by the decreased degradation of GLP‐1 associated with the reduced proportion of TCRαβ+ CD8αβ+ IELs and decreased expression of CD26/DPP‐4 in IELs, as well as the increased GLP‐1 secretion by ...
Pengfei Li, Yong Zhang, Hedong Lang, Pengfei Hou, Yu Yao, Ruiliang Zhang, Xiaolan Wang, Qianyong Zhang, Mantian Mi, Long Yi   +9 more
wiley   +1 more source

Evolving therapeutic paradigms in ocular graft-versus-host disease. [PDF]

Eye (Lond)
Masalkhi M, Wahoud N, Moran B, Elhassadi E.   +3 more
europepmc   +1 more source

Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review. [PDF]

Children (Basel)
Todor SB, Ichim C.
europepmc   +1 more source

A rapidly growing breast tumour in a young woman

JEADV Clinical Practice, EarlyView.
K. A. Zub Carlsson, S. Spetalen, K. M. A. S. Endre, T. O. A. Hegna, G. E. Tjønnfjord, G. Lehne, Ø. Sandanger   +6 more
wiley   +1 more source

Preventive hyperbaric oxygen therapy improves acute graft-versus-host disease by activating the Nrf2/HO-1 pathway. [PDF]

Front Immunol
Xue C, Chen H, Zhao Y, Yuan D, Fang X, Ding M, Qu H, Wang X, Ge X, Lu K, Jiang Y.   +10 more
europepmc   +1 more source

Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice. [PDF]

Biomark Res
Ehx G, Ritacco C, Baron F.
europepmc   +1 more source